Our Technology
A fully integrated AI + biotech platform for deterministic antibody engineering and production
Core Technology Stack
Proprietary CHO Cell Line Platform
Our engineered CHO cell line is optimized for high yield, industrial scalability, and consistent product quality.
- High expression potential
- Adapted to serum-free suspension culture
- Well-characterized genomic background
- GMP-compliant master cell bank
CRISPR Site-Specific Integration
Our CRISPR-based targeted integration technology enables precise insertion of antibody genes into defined genomic "safe harbor" loci.
- Defined integration site
- Reduced clonal variability
- Predictable expression levels
- Faster clone selection
UCOE-based Stable Expression
Our Universal Chromatin Opening Element (UCOE) technology prevents epigenetic silencing, ensuring long-term stable expression.
- Silencing-resistant expression
- Consistent productivity over generations
- Reduced positional effect variation
- Higher overall yields
Antibody LLM Platform
A closed-loop AI system that revolutionizes antibody discovery and optimization
How It Works
Input & Design
Input your target antigen or desired antibody properties, and our LLM generates candidate sequences optimized for affinity, stability, and developability.
In Silico Validation
Our predictive models simulate binding affinity, expression levels, immunogenicity risk, and other critical properties to prioritize the most promising candidates.
Wet Lab Validation
Top candidates are synthesized, expressed, and functionally validated in our lab, generating real-world data to further train our models.
Iterative Improvement
Experimental results are fed back into the model, creating a closed-loop system that continuously improves prediction accuracy over time.
From in silico to in vitro — seamlessly, and faster than ever before.
Key Advantages
Project success rate
Higher expression yields
Faster development timelines
Scalable production